Amarin Corp Plc (AMRN)

[roadkilll]

Always up to companies to defend their drugs against patent abuse. Get aggressive now that the Supreme Court looked at Teva being fined $285 million for infringing a GSK use patent. Target generic manufacturers to enforce skinny labels take actions to halt infringement or pull their drug.
CV added protection is the primary patent of use of Vascepa. Not a frivolous use patent created to extend patent protection.